Cisplatin modulates tumor cell susceptibility to tumor-infiltrating lymphocytes in vivo

Oncology Reports

Volumn 4, Issue 5, 1997, Pages 927-930

  Noguchi, Kohei ^a   Tanimura, Hiroshi ^a   Yamaue, Hiroki ^a   Iwahashi, Makoto ^a   Tsunoda, Takuya ^a   Tani, Masaji ^a   Hotta, Tsukasa ^a   Mizobata, Shizuma ^a   Arii, Kazuo ^a   Tamai, Mikiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Cisplatin; Malignant ascites; Tumor infiltrating lymphocytes

Indexed keywords

CISPLATIN;

ADOPTIVE TRANSFER; ARTICLE; ASCITES; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; MALIGNANT MESOTHELIOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0030740681     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.4.5.927     Document Type: Article

References (23)

1. Rosenberg SA, Sepiess P, Latreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
2. Kradin RL, Boyle LA, Pleffer FI, Callahan RJ, Barlai-Kovach M, Strauss HM, Dubinett S, Kurnick JT: Tumor-derived interleukin-2 dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 24: 76-85, 1987.
3. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalin SL, Toy ST, Simon P, Lotze MT, Yang JG, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Eng J Med 319: 1676-1680, 1988.
4. Kradin RL, Kurnick JT, Lazarus DS, Pleffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW: Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet i: 577-580, 1989.
5. Stoychkov JN, Schultz RM, Chirigos MA, Pavlidis NA, Goldin A: Effect of adriamycin and cyclophosphamide treatment on induction of macrophage cytotoxic function in mice. Cancer Res 39: 3014-3019, 1979.
6. Matheson DS, Green BJ, Hoar DI: The influence of methotrexate and thymidine on the human natural killer cell function in vitro. J Immunol 131: 1619-1621, 1983.
7. Wang BS, Lumangias AL, Ruszala-Mallon VM, Durr FE: Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracene-dicarboxaldehyde bis [(4,5-dihydro-1H-imidazole-2-yl) hydrazone] dihydrochloride (bisantrene). Cancer Res 44: 2363-2367, 1984.
8. Rosenberg B, Van Camp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698-699, 1965.
9. Collins JL, Kao MS: The anticancer drug, cisplatin, increase the naturally occurring cell-mediated lysis of tumor cells. Cancer Immunol Immunother 29: 17-22, 1989.
10. Mizutani Y, Bonavida B, Nio Y, Yoshida O: Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells. Cancer 71: 1313-1321, 1993.
11. Yamaue H, Tanimura H, Noguchi K, Iwahashi M, Tsunoda T, Tani M, Tamai M, Hotta T, Mizobata S, Arii K: Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J Clin Lab Immunol 35: 165-170, 1991.
12. Kleinerman ES, Zwelling LA, Howser D, Young RC, Decker JM, Bull J, Muchmore AV: Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet ii: 1102-1105, 1980.
13. Kiyohara T, Taniguchi K, Kubota S, Koga S, Sakaguchi T, Saito Y: Induction of lymphokine-activated killer cells by cancer chemotherapy. J Exp Med 168: 2355-2360, 1988.
14. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T: Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 51: 1934-1939, 1991.
15. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Tamai M, Inoue M: Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes. Biotherapy 4: 473-477, 1990.
16. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int J Cancer 60: 1-6, 1995.
17. Crum ED: Effect of cisplatin upon expression of in vivo immune tumor resistance. Cancer Immunol Immunother 36: 18-24, 1993.
18. Gold JE, Masters TR, Babbit B, Fine EM, Weber HN, Unger PD, Leventhal I, Zippe CD, Osband ME: Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumor targets with potentiation by cis-diamminedichloroplatinum (II). Br J Urol 76: 115-122, 1995.
19. Kondo S, Barna BP, Morimura T, Takeuchi J, Yuan J, Akbasak A, Barnett GH: Interleukin-1β-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res 55: 6166-6171, 1995.
20. Morimoto H, Yonehara S, Bonavida B: Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 53: 2591-2596, 1993.
21. Barth RJ, Mule JJ, Asher AL, Sanda MG, Rosenberg SA: Identification of unique murine tumor associated antigens by tumor-infiltrating lymphocytes using tumor specific secretion of interferon γ and tumor necrosis factor. J Immunol Methods 140: 269-279, 1991.
22. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178, 1993.
23. Trapani JA, Browne KA, Smyth MJ, Jans DA: Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem 271: 4127-4133, 1996.